-Reuters
Pfizer Announced Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial; Said Study Demonstrated Statistically Significant Reduction In Annualized Bleeding Rate Vs Prophylaxis, On-demand Intravenous Regimens
Pfizer Inc. (NYSE:PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically